NCT00574132 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer’s Disease Who Are Apolipoprotein E4 Non- Carriers Posted on December 12, 2019 by tsuperadmin -
NCT00575055 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer’s Disease Who Are Apolipoprotein E4 Carriers Posted on December 12, 2019 by tsuperadmin -
Placebo-controlled evaluation of galantamine in the treatment of Alzheimer’s disease: Evaluation of safety and efficacy under a slow titration regimen Posted on January 10, 2018 by tsuperadmin -
A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in patients with a diagnosis of senile dementia of the Alzheimer’s type Posted on October 13, 2017 by tsuperadmin -
NCT00082602 – Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer’s Disease Posted on September 20, 2017 by tsuperadmin -
Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial Posted on September 7, 2017 by tsuperadmin -
NCT00645190 – A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer’s Disease:Safety and Effectiveness of an Immediate-release Table Formulation. Posted on September 7, 2017 by tsuperadmin -
NCT00216593 – Treatment of Severe Alzheimer’s Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study Posted on March 30, 2017 by tsuperadmin -
NCT00679627 – A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer’s Disease Posted on August 3, 2016 by tsuperadmin -
Galantamine treatment of vascular dementia: a randomized trial Posted on June 8, 2016 by tsuperadmin -
The YODA Project